Hemophilia is a disorder in which the blood does not clot properly, leading to extended bleeding. The bleeding can be external or internal, especially in the knees, ankles, and elbows. There are two types of hemophilia: type A and type B. The market has been growing since past several years mainly due to improvement in technology, discovery of new coagulation factors, proteins, and plasma concentrates which are being used for treating chronic diseases and medical conditions. As more people suffer with Hemophilia A in comparison with Hemophilia B and Inhibitors, the Hemophilia A market is the largest in the world. The US accounts for the major population suffering with hemophilia globally. The key trends observed within the market include inclination towards prophylaxis, long-acting factor VIII and IX development and growing penetration of rFVIII products in emerging markets which is a opportunity for manufacturers. On the development front, there has been an increase in the launch of new products by various companies. But there are certain challenges which the industry is facing as of now which include risk of antibody neutralization, emerging challenges for developing nations and rising cost of hemophilia treatment. The major factors which will contribute in the growth of the industry include rising male population, increasing expenditure on healthcare and increasing new patient registration. The report studies the hemophilia market on a global scale and its various segments. The competition in the global hemophilia market is intense with few large players viz. Baxter, Grifols, Pfizer and Nova Noridisk. The competitive landscape along with the company profiles of the leading players in the market is discussed in detail.

1. Global Hemophilia Market
--------------------------------------------
2013
View Report Details

2. Executive Summary
Hemophilia is a disorder in which the blood does not clot properly, leading to extended bleeding. The bleeding
can be external or internal, specially in the knees, ankles, and elbows. There are two types of hemophilia: type
A and type B. The market has been growing since past several years mainly due to improvement in
technology, discovery of new coagulation factors, proteins, and plasma concentrates which are being used for
treating chronic diseases and medical conditions.
As more people suffer with Hemophilia A in comparison with Hemophilia B and Inhibitors, the Hemophilia A
market is the largest in the world. The US accounts for the major population suffering with hemophilia globally.
The key trends observed within the market include inclination towards prophylaxis, long-acting factor VIII and
IX development and growing penetration of rFVIII products in emerging markets which is a opportunity for
manufacturers. On the development front, there has been an increase in the launch of new products by
various companies. But there are certain challenges which the industry is facing as of now which include risk
of antibody neutralization, emerging challenges for developing nations and rising cost of hemophilia treatment.
The major factors which will contribute in the growth of the industry include rising male population, increasing
expenditure on healthcare and increasing new patient registration.
The report studies the hemophilia market on a global scale and its various segments. The competition in the
global hemophilia market is intense with few large players viz. Baxter, Grifols, Pfizer and Nova Noridisk. The
competitive landscape along with the company profiles of the leading players in the market is discussed in
detail.
By combining SPSS Inc.’s data integration and analysis capabilities with our relevant findings, we have
predicted the future growth of the industry. We employed various significant variables that have an impact on
this industry and created regression models with SPSS Base to determine the future direction of the industry.
Before deploying the regression model, the relationship between several independent or predictor variables
and the dependent variable was analyzed using standard SPSS output, including charts, tables and tests.
View Report Details

3. Hemophilia is linked to recessive X genes, which leads to the inability to synthesize clotting
factor…..
 The number of patients treated with hemophilia increased
from …… in 2010 to ……. in 2011 showing a growth of
…..%. In 2012, the numbers of patients treated with
hemophilia were estimated to have increased to …….
showing a rise of …….% in comparison with 2011.
The global hemophilia treatment market revenues showed
a growth of …..% rising from US$....... billion in 2010 to
US$....... billion in 2011. In 2012, the market was estimated
to have reached US$........ billion showing an increase of
…..% in comparison with 2011.
Industry Developments :
-Baxter Announced ADVATE Approval in China for the
Treatment of Hemophilia A
- Baxter Expands Access to Recombinant FVIII Hemophilia
Treatment in Brazil
- Novo Nordisk Files New Hemophilia Drug in EU, US
Industry Key Trends :
-Shift towards Prophylaxis
- Long-Acting Factor VIII and IX Development
- Rising Penetration of rFVIII Products in Emerging Markets
Market Growth Drivers
- Rising Male Population
- Increasing Expenditure on Healthcare
-Increasing New Patient Registration
Challenges
-Risk of Antibody Neutralization
- Emerging Challenges for Developing Nations
-Rising Cost of Hemophilia Treatment
Number of Treated Patients with Hemophilia (2010-2012E)
Global Hemophilia Treatment Market Revenues (2008-2012E)
2010 2011 2012E
2008 2009 2010 2011 2012E
US$Billion

4. Globally, patients suffering from Hemophilia A was more than Hemophilia B and patients
with identifier……
In 2011, the numbers of patients treated with hemophilia A were ……
showing an increase of ……. % from …….. patients in 2010. The
numbers of patients treated with hemophilia A were estimated to be
…….. in 2012 showing a growth of …….%.
The number of patients treated with Hemophilia B increased from
……. in 2010 to ……. in 2011 showing a rise of ……%. The same was
estimated to have increased by ……% in 2012 in comparison with
2011.
 There were ……. patients globally with inhibitors in 2011 which
increased by ……% in comparison with 2010, and the vast majority
were hemophilia A patients. In 2012, the numbers of patients with
inhibitors were estimated to be ……. showing a growth of ……% as
compared to 2011.
Number of Treated Patients with Hemophilia B (2010-2012E)
Number of Treated Patients with Hemophilia A (2010-2012E)
2010 2011 2012E
2010 2011 2012E
Number of Patients Identified with Inhibitor (2010-2012E)
2010 2011 2012E

5. The Global Hemophilia Market is highly fragmented and companies face intense
competition. In 2011, the market leader was Baxter.
The number of people treated with hemophilia in the United States was ….. in 2010 which increased to …… in 2011 showing a rise
of ……%. The same was estimated to rise to …….. in 2012 witnessing a growth of …..% in comparison with 2011.
On the competition front, Baxter was the leading company in the hemophilia market world over, with approximately ……% of the
market share for the year 2011, followed by Novo Nordisk and Pfizer with ……% and ….. % respectively.
 The global hemophilia market increased from US$...... billion in 2011 to US$...... billion in 2012 showing an increase of …..%. The
market is forecasted to reach US$..... billion in 2013 showing a rise of ……%. The global hemophilia treatment market is expected to
grow at a CAGR of …..% for the period spanning 2011-2016.
Note: Market attractiveness is inverse of penetration. Low penetration means high attractiveness and vice-versa
2011 2012 2013F 2014F 2015F 2016F
US$Billion
Global Hemophilia Treatment Market Forecast (2011-2016F)
2010 2011 2012E
No. of Hemophilia Patients Treated in the US (2010-2012E)

6. Table of Contents
1. Hemophilia: An Overview
-Sign & Symptoms
-Types of Hemophilia
-Treatment
2. Market Overview
2.1 Global Hemophilia Market
-Market Value
-Patient Volume
2.2 Hemophilia Market by Segments
2.2.1 Hemophilia A
-Market Value
-Patient Volume
-Key Products Comparison
-FVIII Market
2.2.2 Hemophilia B
-Market Value
-Patient Volume
-Key Products Comparison
-FIX Market
List of Graphs & Tables
List of Charts
Types of Hemophilia
Worldwide Patients Treated with Hemophilia (2010-2012E)
Global Hemophilia Treatment Market Revenues (2008-2013E)
Worldwide Patients Treated with Hemophilia A (2010-2012E)
Global Hemophilia A Market Size (2010-2012E)
Global Recombinant FVIII Market Revenues (2005-2012E)
Worldwide Patients Treated with Hemophilia B (2010-2012E)
Global Hemophilia B Market Size (2010-2012E)
Global Recombinant FIX Market Size (2006-2012E)
Global Recombinant FIX Consumption (2005-2011)
Global Recombinant FIX Consumption Market Share (2011)
Worldwide Patients Treated with Inhibitor (2010-2012E)
Global Inhibitor Market Size (2010-2013E)
Demand of Plasma Derived Factor IX in Australia (2008-2012)
Demand of Recombinant Factor IX in Australia (2008-2012)
Number of Hemophilia Patients Treated in the US (2010-2012E)
The US Hemophilia Market Value (2010-2012E)
Global Male Population (2005-2014F)
Healthcare Expenditure Worldwide (2005-2012E)
New Patient Registrations in Global Bleeding Disorders Market (2008-
2012)
Global Hemophilia Market Share (2011)
Global Recombinant Coagulation (FVII, FVIII, FIX) Market (2011)

7. 2.2.3 Hemophilia with Inhibitor
-Market Value
-Patient Volume
-Key Products
2.2.4 Von Willebrand Disease
2.3 Hemophilia Market by Region
2.3.1 Australia
2.3.2 The US
-Market Value
-Patient Volume
-Market Segments
-FVIII Market
-FIX Market
3. Market Dynamics
3.1 Key Trends
3.1.1 Shift towards Prophylaxis
3.1.2 Long-Acting Factor VIII and IX Development
3.1.3 Rising Penetration of rFVIII Products in Emerging Markets
3.2 Growth Drivers
Global Recombinant FVIII Market Share (2012E)
Baxter’s Revenue by Business Segments (2012)
Baxter’s Revenues and Net Income (2008-2012)
Grifols Revenue Share by Business Segments (2012)
Grifols Revenue Share by Geographical Segments (2012)
Grifols’ Revenues & Net Profit (2008-2012)
Novo Nordisk’s Revenue Share by Business Segments (2012)
Novo Nordisk’s Revenue Share by Region (2012)
Sales and Net Income of Novo-Nordisk (2008-2012)
Pfizer’s Revenue Share by Business Segments (2012)
Pfizer’s Revenue Share by Geographical Segments (2012)
Pfizer’s Revenues & Net Income (2008-2012)
Global Hemophilia Treatment Market Forecast (2011-2016F)
Tables
Revenues of Key Products in Hemophilia A Treatment Market (2011-
2016F)
Products for Hemophilia A Treatment
Products for Treatment of Hemophilia B
Inhibitor Treatment (2010-2012E)
US Hemophilia Market by Segments (2010-2012E)
Volume of FVIII Market in the US (2008-2012)
US FIX Consumption (2005-2011)
US Factor (M IU) Consumption by Treatment Type and Patient Age
(2012-2020)
Hemophilia A patients by Treatment Category (2012)
Long Acting FIX & FVIII in Early and Late-Stage Development

8. 3.2.1 Rising Male Population
3.2.2 Increasing Expenditure on Healthcare
3.2.3 Increasing New Patient Registration
3.3 Significant Developments
3.3.1 Baxter Announced ADVATE Approval in China
3.3.2 Baxter Expands Access to Recombinant FVIII Hemophilia
Treatment in Brazil
3.3.3 Novo Nordisk Files New Hemophilia Drug in EU, US
3.4 Challenges
3.4.1 Risk of Antibody Neutralization
3.4.2 Emerging Challenges for Developing Nations
3.4.3 Rising Cost of Hemophilia Treatment
4. Competitive Scenario
-Market Share
-Product Comparison
5. Company Profiles
5.1 Baxter International Inc.
% Conversion to Recombinant Factor VIII Products in Selected
Countries (2011)
Competition in Hemophilia A Market – Emerging Products
Competition in Hemophilia B Market – Emerging Products
Competition in Inhibitor Market – Emerging Products
Competition in von Willebrand Market – Emerging Products
Dependent & Independent Variables (2008-2012)
Correlation Matrix
Model Summary – Coefficient of Determination
Regression Coefficients Output

9. 5.1.1 Business Overview
5.1.2 Financial Overview
5.1.3 Business Strategies
-Advancement of Core Portfolio
-Expansion of Product Portfolio
5.2 Grifols
5.2.1 Business Overview
5.2.2 Financial Overview
5.2.3 Business Strategies
-Expansion in Other Geographic Regions
-Growth through Mergers & Acquisitions
5.3 Novo Nordisk
5.3.1 Business Description
5.3.2 Financial Highlights
5.3.3 Business Strategies
-Product Innovation
5.4 Pfizer, Inc.
5.4.1 Business Overview
5.4.2 Financial Highlights
5.4.3 Business Strategies
-Expansion in Emerging Markets
-Growth through Acquisitions

10. 6. Market Outlook
6.1 Market Forecast
6.2 Forecast Methodology
6.2.1 Dependent and Independent Variables
6.2.2 Correlation Analysis
6.2.3 Regression Analysis

11. Koncept Analytics
CS-36, Second Floor, Ansal Plaza
Vaishali, Ghaziabad,
U.P. – 201010
T. +91-120-4130959
C: +91-9811715635
vikas@konceptanalytics.com
Contact Us:
www.konceptanalytics.com
Vikas Gupta
BD Manager
These are abridged and sanitized sample pages from the comprehensive report on the “Global Hemophilia Market”. To know
more about this report or for any customized research requirement, please contact the following:
View Report Details